A031203: Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
CTO - 8565
Cancer - Genitourinary/ Prostate/ Kidney
Principal Investigator: Robert A Chapman, MD
This randomized phase II trial studies how well giving cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated locally advanced or metastatic kidney cancer. Cabozantinib-s-malate and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cabozantinib-s-malate or sunitinib malate is more effective in treating patients with kidney cancer.
- Males and females at least 18 years of age
- Histologic documentation: renal cell carcinoma with some component of clear cell histology; histologic documentation of metastatic disease is not required